• Mashup Score: 0

    W. Schuyler Jones, MD, and Manesh Patel, MD discuss the influences the aspirin-dosing cardiology trial may have on future studies.

    Tweet Tweets with this article
    • Data from the #ADAPTABLE trial was presented at #ACC20 this year. HCPLive spoke with @schuyler_jones about the biggest takeaways from the study on Ep 1 of the #HeartTrials podcast. How might this trial potentially influence future clinical trials? https://t.co/1aE8dDL6tj https://t.co/DwLBvVYpKe

  • Mashup Score: 0

    Young Black women have health conditions that may put them at greater risk to develop heart disease, according to a study released Tuesday by a team of Emory University researchers.

    Tweet Tweets with this article
    • Young Black women at greater risk of heart disease, TODAY at 9:30 ET Abstract Presentation from Dr Nishant Vatsa ⁦@EmoryDeptofMed⁩ ⁦@emorywomenheart⁩ ⁦@emoryheart⁩ #10KWomen #ACC20 #ACCPrev #HTN ⁦@DrTelisa⁩ ⁦@PujaKMehtaMD1⁩ https://t.co/GNQihQ1mST

  • Mashup Score: 5

    Without a doubt, the top news of 2020 was the COVID-19 pandemic. From the beginning, ACC was at the forefront of generating clinical guidance, providing expert commentary and facilitating the sharing of new research and front-line perspectives. Top articles include Cardiology magazine features on the risk of infectious agents and an exclusive interview with…

    Tweet Tweets with this article
    • Although #COVID19 dominated the 2020 news cycle, ACC covered much more clinical news on #CVD. Hot clinical trials like RIVER, DAPA-CKD, and made headlines from major meetings, including #ACC20 Virtual. Read on to see top 2020 ACC news stories: https://t.co/9IZ1XOfMrp https://t.co/1JAsb2BtAP

  • Mashup Score: 0

    Medtronic announced that the FDA approved an expanded indication for a drug-eluting stent to include patients with high bleeding risk who take dual antiplatelet therapy for 1 month after PCI.The DES (Resolute Onyx) is the first and only stent in the U.S. that is safe and effective in this particular patient population, according to a press release from the company.

    Tweet Tweets with this article
    • .@US_FDA approves expanded indication for DES to include patients w/ high bleeding risk who take #DAPT antiplatelet therapy for 1 mo. after #PCI. Approval comes based on the results of Onyx ONE Clear study presented at #ACC20. @CardiologyToday: https://t.co/IZ4hxGloNj

  • Mashup Score: 0

    A phase 3 pivotal trial of MyoKardia’s mavacamten has demonstrated that the first-in-class drug can perform as a disease-specific therapy for hypertrophic cardiomyopathy, or HCM, by preventing the thickened heart muscle associated with the disease from obstructing the flow of blood.

    Tweet Tweets with this article
    • At #ACC20, MyoKardia presented phase 2 data showing mavacamten could significantly ⬇ blood levels of cardiac troponin I & NT-proBNP among patients w/ non-obstructive HCM. Similar reductions were seen in the Explorer study at #ESCCongress. @FierceBiotech: https://t.co/KELLDdnXka